News and Trends / Legal Issues

Will the DEA Reclassify CBD?

The agency takes another look at cannabidiols.
Will the DEA Reclassify CBD?
Image credit: Bloomberg Creative Photos | Getty Images
Guest Writer
Easy Search. Quality Finds. Your partner and digital portal for the cannabis community.
3 min read
Opinions expressed by Green Entrepreneur contributors are their own.

Approval by the Food and Drug Administration of a new drug that contains cannabidiols could prove to be the step needed for the Drug Enforcement Agency to reclassify at least one derivative of marijuana.

Cannabidiols--known as CBD--are used in the drug Epidiolex. In June, the FDA approved the use of the drug for children who experience severe epileptic seizures. The drug includes CBD taken from marijuana plants.

CBD does not cause the “high” associated with cannabis.

It’s the first cannabis-based drug approved by the FDA. That’s a big enough deal, but it also might force an equally groundbreaking decision.

Related: These Pot Store Names Are Just the Greatest

In the DEA’s court.

The federal government lists marijuana as a Schedule I drug--the highest level for an illegal drug. To give you some perspective, other Schedule I drugs include heroin, LSD, mescaline and methylenedioxymethamphetamine (better known as “ecstasy”).

Getting listed as Schedule I means a drug has a high potential for abuse and no health benefits.

Clearly, the FDA decision on Epidiolex contradicts that stance on marijuana--at least when it comes to CBD. An advisory committee for the FDA referred to the Schedule 1 status of CBD in reporting its decision to the DEA, which is part of government protocol in these situations. The committee wrote: “An overall assessment of the abuse-related data from preclinical and clinical studies leads to the finding that CBD has negligible abuse potential.”

The DEA now must consider whether to reclassify CBD as a legal substance. That could potentially have a significant impact on the marijuana industry, where CBD products are increasingly popular.

Related: Before Heading To Canada To Buy Weed, Read This

What Epidiolex does.

The Epidiolex drug is aimed at treating both Dravet and Lennox-Gastaut syndromes. Both cause severe, daily seizures. Typically, the syndromes begin at a very young age, which is why the FDA approved use of the drug for those ages two or older.

Epidiolex is the only drug approved for treatment of Dravet syndrome, according to the Washington Post.

London-based GW Pharmaceuticals developed Epidiolex. In a press release, the company said rescheduling by the DEA will be needed to make the drug available to patients everywhere in the U.S..

“Rescheduling is expected to occur within 90 days,” the company reported, adding that Epidiolex should be available to “appropriate patients” by the fall of this year.

In approving the drug, the FDA noted that the approval of Epidiolex shows how new drugs can be developed if proper procedures are followed. The FDA has voiced concerns in the past about CBD products hitting the market that make health claims not backed up by rigorous research and clinical trials.

Follow dispensaries.com on Instagram to stay up to date on the latest cannabis news.

By Javier Hasse
From retailers to growers, producers, and suppliers, there’s a seemingly never-ending list of startup opportunities in this emerging market. In Start Your Own Cannabis Business, marijuana, biotech, and entrepreneurship reporter Javier Hasse introduces forward-thinking entrepreneurs like you to the industry and shares hard-earned tips and success stories from pioneers and visionaries in the marijuana industry.
Learn More

Latest on Green Entrepreneur

My Queue

There are no Videos in your queue.

Click on the Add to Queue next to any video to save to your queue.

There are no Articles in your queue.

Click on the Add to Queue next to any article to save to your queue.

Podcasts episodes coming soon for GreenEntrepreneur.com

There are no Podcasts in your queue.

Click on the Add to Queue next to any podcast episode on Entrepreneur.com to save to your queue.

You're not following any authors.

Click the Follow button on any author page to keep up with the latest content from your favorite authors.

Entrepreneur Media, Inc. values your privacy. In order to understand how people use our site generally, and to create more valuable experiences for you, we may collect data about your use of this site (both directly and through our partners). The table below describes in more detail the data being collected. By giving your consent below, you are agreeing to the use of that data. For more information on our data policies, please visit our Cookie Policy.

Name Category
Google Ad Serving, Ad Targeting, Analytics/Measurement, Optimisation
Rubicon Ad Serving
Teads Ad Serving
Nativo Ad Serving
Teads Ad Serving
New Relic Analytics/Measurement
Log Entries Analytics/Measurement
Sailthru Content Customization